documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
27 rows where docket_id = "FDA-2020-Q-1295" sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: subtype, posted_date, posted_month, comment_start_date, posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)
document_type 2
agency_id 1
- FDA 27
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2020-Q-1295-0026 | FDA | None FDA-2020-Q-1295 | Withdrawal request for docket number FDA-2020-Q-1295 | Other | Withdrawal | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2023-12-28T18:40:58Z | 0 | 0 | 0900006486364403 | ||
| FDA-2020-Q-1295-0027 | FDA | None FDA-2020-Q-1295 | FDA response to a withdrawal request for CA and Migraine Final | Other | Acknowledgement Letter/Receipt | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2023-12-28T18:41:04Z | 0 | 0 | 0900006486364405 | ||
| FDA-2020-Q-1295-0021 | FDA | None FDA-2020-Q-1295 | Reference 16 - Insulin and Ketone Responses to Ingestion of Medium and Long-chain Triglyercides in Man | Supporting & Related Material | Background Material | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T12:58:09Z | 0 | 0 | 09000064844f9fd1 | |||
| FDA-2020-Q-1295-0003 | FDA | None FDA-2020-Q-1295 | Filing Letter signed | Other | Letter(s) | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T04:00:00Z | 2020-04-30T12:56:00Z | 0 | 0 | 09000064844fb10e | ||
| FDA-2020-Q-1295-0025 | FDA | None FDA-2020-Q-1295 | Reference 20 - A new way to produce hyperketonemia - Use of ketone ester in a case of Alzheimer's Disease | Supporting & Related Material | Background Material | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T12:58:35Z | 0 | 0 | 09000064844f9fd5 | |||
| FDA-2020-Q-1295-0015 | FDA | None FDA-2020-Q-1295 | Reference 10 - Treatment of Parkinson Disease with Diet Induced Hyperketonemia - A Feasibillity Study | Supporting & Related Material | Background Material | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T12:57:23Z | 0 | 0 | 09000064844fb167 | |||
| FDA-2020-Q-1295-0022 | FDA | None FDA-2020-Q-1295 | Reference 17 - Hyperketonemia Induced in Man by Medium-Chain Triglyceride | Supporting & Related Material | Background Material | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T12:58:16Z | 0 | 0 | 09000064844f9fd2 | |||
| FDA-2020-Q-1295-0014 | FDA | None FDA-2020-Q-1295 | Reference 9 - Migraine improvement during short lasting ketogenesis - a proof-of-concept study | Supporting & Related Material | Background Material | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T12:57:17Z | 0 | 0 | 09000064844fb166 | |||
| FDA-2020-Q-1295-0018 | FDA | None FDA-2020-Q-1295 | Reference 13 - Can Ketosis Help Migraine Sufferers A Case Study | Supporting & Related Material | Background Material | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T12:57:47Z | 0 | 0 | 09000064844f9fce | |||
| FDA-2020-Q-1295-0024 | FDA | None FDA-2020-Q-1295 | Reference 19 - Composition of Weight Lost during Short-Term Weight Reduction | Supporting & Related Material | Background Material | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T12:58:28Z | 0 | 0 | 09000064844f9fd4 | |||
| FDA-2020-Q-1295-0007 | FDA | None FDA-2020-Q-1295 | Reference 2 - Ketones - Metabolism's Ugly Duckling | Supporting & Related Material | Background Material | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T12:56:30Z | 0 | 0 | 09000064844fb115 | |||
| FDA-2020-Q-1295-0013 | FDA | None FDA-2020-Q-1295 | Reference 8 - Ketone body therapy - from the ketogenic diet to the oral administration of ketone ester | Supporting & Related Material | Background Material | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T12:57:10Z | 0 | 0 | 09000064844fb165 | |||
| FDA-2020-Q-1295-0019 | FDA | None FDA-2020-Q-1295 | Reference 14 - Diet transiently improves migraine in two twin sisters- possible role of Ketogenesis | Supporting & Related Material | Background Material | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T12:57:54Z | 0 | 0 | 09000064844f9fcf | |||
| FDA-2020-Q-1295-0004 | FDA | None FDA-2020-Q-1295 | Appendix B | Supporting & Related Material | Background Material | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T12:56:10Z | 0 | 0 | 09000064844fb112 | |||
| FDA-2020-Q-1295-0001 | FDA | None FDA-2020-Q-1295 | QHC Petition for Caprylic and Capric Acid and Migraine | Other | Qualified Health Claims | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T04:00:00Z | 2020-06-30T03:59:59Z | 2020-04-30T12:55:43Z | 0 | 0 | 09000064844fb10c | |
| FDA-2020-Q-1295-0011 | FDA | None FDA-2020-Q-1295 | Reference 6 - Potential Protective Mechanisms of Ketone Bodies in Migraine Prevention | Supporting & Related Material | Background Material | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T12:56:58Z | 0 | 0 | 09000064844fb163 | |||
| FDA-2020-Q-1295-0006 | FDA | None FDA-2020-Q-1295 | Reference 1 - Studies Compare the Burdens of Chronic and Episodic Migraine | Supporting & Related Material | Background Material | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T12:56:22Z | 0 | 0 | 09000064844fb114 | |||
| FDA-2020-Q-1295-0023 | FDA | None FDA-2020-Q-1295 | Reference 18 - Starvation-Induced Ketosis - Reduction in Dogs Enriched with Odd-Carbon Fatty Acids | Supporting & Related Material | Background Material | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T12:58:22Z | 0 | 0 | 09000064844f9fd3 | |||
| FDA-2020-Q-1295-0008 | FDA | None FDA-2020-Q-1295 | Reference 3 - A study of oxidative stress in migraine with special reference to prophylactic therapy | Supporting & Related Material | Background Material | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T12:56:36Z | 0 | 0 | 09000064844fb160 | |||
| FDA-2020-Q-1295-0020 | FDA | None FDA-2020-Q-1295 | Reference 15 Cortical functional correlates of responsiveness to short lasting preventive intrvention with | Supporting & Related Material | Background Material | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T12:58:03Z | 0 | 0 | 09000064844f9fd0 | |||
| FDA-2020-Q-1295-0010 | FDA | None FDA-2020-Q-1295 | Reference 5 - The ketone metabolite hydroxybutyrate blocks NLRP3 Inflamatory Mediated Inflamatory Disease | Supporting & Related Material | Background Material | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T12:56:49Z | 0 | 0 | 09000064844fb162 | |||
| FDA-2020-Q-1295-0002 | FDA | None FDA-2020-Q-1295 | Acknowledgment Letter | Other | Acknowledgement Letter/Receipt | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T04:00:00Z | 2020-04-30T12:55:53Z | 0 | 0 | 09000064844fb10d | ||
| FDA-2020-Q-1295-0016 | FDA | None FDA-2020-Q-1295 | Reference 11 - Biomarkers, ketone bodies, and the prevention of Alzheimer's Disease | Supporting & Related Material | Background Material | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T12:57:30Z | 0 | 0 | 09000064844fb169 | |||
| FDA-2020-Q-1295-0005 | FDA | None FDA-2020-Q-1295 | Appendix C | Supporting & Related Material | Background Material | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T12:56:16Z | 0 | 0 | 09000064844fb113 | |||
| FDA-2020-Q-1295-0009 | FDA | None FDA-2020-Q-1295 | Reference 4 - Modulation of oxidative stress and mitochondrial function by the ketogenic diet | Supporting & Related Material | Background Material | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T12:56:43Z | 0 | 0 | 09000064844fb161 | |||
| FDA-2020-Q-1295-0012 | FDA | None FDA-2020-Q-1295 | Reference 7 - Ketogenic diet in migraine treatment-A Brief but Ancient History | Supporting & Related Material | Background Material | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T12:57:03Z | 0 | 0 | 09000064844fb164 | |||
| FDA-2020-Q-1295-0017 | FDA | None FDA-2020-Q-1295 | Reference 12 - An Experience with a Ketogenic Dietary in Migraine | Supporting & Related Material | Background Material | 2020-04-30T04:00:00Z | 2020 | 4 | 2020-04-30T12:57:40Z | 0 | 0 | 09000064844f9fcd |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;